A joint study by the National Neuroscience Institute (NNI) and Singapore General Hospital (SGH) revealed that patients who have been diagnosed with Parkinson's disease might actually have NIID instead.
NIID is a disabling neurodegenerative condition due to a gene mutation and has no effective treatment. Symptoms of NIID include dementia, Parkinsonism, poor balance, as well as numbness and weakness in the limbs. A patient with NIID may or may not experience symptoms, depending on age and stage of disease. The severe form of NIID is usually seen in older patients, where the disease has progressed to an advanced stage.
The team studied more than 2,000 study participants, comprising healthy individuals and those with Parkinson's disease (PD), over more than a decade. They were surprised to find NIID-causing mutations in those diagnosed with PD. Dr Ma Dongrui, Senior Medical Laboratory Scientist, Department of Neurology, SGH, and first author of the study explains, "To our knowledge, this is the first study reporting PD patients with NOTCH2NLC gene mutations as seen in NIID patients. Thankfully, they responded to PD medications better than most PD patients do. This suggests that there must be factors that can influence why some develop PD while many others develop the more severe form of NIID.
While analysing the NIID gene, the team found a group of healthy participants who had a "milder" form of mutation. Such mutation in the NIID gene could indicate that they are at risk of developing NIID or PD.
Since NIID can go undetected, a high index of suspicion may be needed even in PD patients. "With what we know now, it might be beneficial for clinicians to be watchful of early cognitive impairment or imaging evidence that may suggest NIID in patientsdiagnosed with PD. As NIID is caused by a genetic mutation, it also may be worth looking out for family members of PD patients who may show signs of NIID," suggests Professor Tan Eng King, Deputy Medical Director and Director of Research, NNI.
"Our findings suggest that many neurodegenerative diseases overlap and may share a common etiology. Finding a common link and uncovering the reason why a similar gene mutation leads to both mild PD and a severe form of NIID can help identify new drugs for these conditions," continues Prof Tan, who is also the senior author of the study and a Senior Consultant at NNI's Department of Neurology on SGH Campus.
Following this study, the team plans to conduct more studies to better understand the mechanism behind NIID and identify new drugs for this condition. More research is needed to understand if the broad clinical phenotype of NIID is related to the subtle genetic differences at the NOTCH2NLC gene locus, race or other factors. Long-term follow-up of carriers of the gene mutation with PD phenotype may provide additional clues.
The study findings were published online in JAMA Neurology on 24 August 2020.
###
Reference: Dongrui Ma, Yi Jayne Tan, Adeline S. L. Ng, Helen L. Ong, Weiying Sim, Weng Khong Lim, Jing Xian Teo, Ebonne Y. L. Ng, Ee-Chien Lim, Ee-Wei Lim, Ling-Ling Chan, Louis C. S. Tan, Zhao Yi, PhD; Eng-King Tan. Association of NOTCH2NLC Repeat Expansions with Parkinson Disease. JAMA Neurology. Published online August 24, 2020. doi:10.1001/jamaneurol.2020.3023
For more information & interview requests, please contact:
Ms Adriel Lee
Corporate Communications Department
National Neuroscience Institute
Tel: 6357 7107 / 9112 3401
E-mail: Adriel_W_Lee@nni.com.sg
Ms Margaret Perry
Corporate Communications Department
National Neuroscience Institute
Tel: 6357 7162 / 9457 8726
E-mail: Margaret_Ellen_PERRY@nni.com.sg
Ms Carol Ang
Communications Department
Singapore General Hospital
Tel: 9845 5354
Email: carol.ang@sgh.com.sg
About the National Neuroscience Institute (NNI)
The National Neuroscience Institute (NNI) is the national specialist and regional centre of care for the brain, spine, nerve and muscle. NNI offers Neurology, Neurosurgery and Neuroradiology services with advanced technology and multi-disciplinary care teams. Committed to improving patients' lives, NNI aims to shape neuroscience for a better tomorrow through innovation, research and education. NNI is a member of the Singapore Health Services (SingHealth) - a public healthcare cluster which manages four hospitals, five specialty centres, eight polyclinics and a network of community hospitals. For more information, visit http://www.nni.com.sg.
About Singapore General Hospital (SGH)
Singapore General Hospital, a member of Singapore Health Services, is the public sector's flagship hospital. Established in 1821, SGH is Singapore's largest acute tertiary hospital with 1,700 beds and national referral centre offering a comprehensive range of more than 40 clinical specialties on its campus. Every year, about 1 million Singaporeans benefit from medical care delivered by its 800 specialists. As an academic healthcare institution and the bedrock of medical education, SGH plays a key role in nurturing doctors, nurses and allied health professionals, and is committed to innovative translational and clinical research in her continual strive to provide the best care and outcomes to her patients. http://www.sgh.com.sg
Journal
JAMA Neurology